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Oculodentodigital dysplasiaa b s t r a c t
There are now at least 14 distinct diseases linked to germ line mutations in the 21 genes that encode
the connexin (Cx) family of gap junction proteins. This review focuses on the links between germ-
line mutations in the gene encoding Cx43 (GJA1) and the human disease termed oculodentodigital
dysplasia (ODDD). This disease is clinically characterized by soft tissue fusion of the digits, abnormal
craniofacial bone development, small eyes and loss of tooth enamel. However, the disease is consid-
erably more complex and somewhat degenerative as patients often suffer from other syndromic
effects that include incontinence, glaucoma, skin diseases and neuropathies that become more pro-
nounced during aging. The challenge continues to be understanding how distinct Cx43 gene muta-
tions cause such a diverse range of tissue phenotypes and pathophysiological changes while other
Cx43-rich organs are relatively unaffected. This review will provide an overview of many of these
studies and distill some themes and outstanding questions that need to be addressed in the coming
years.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Overview
Gap junctions are intercellular channels that directly link adja-
cent cells to allow for the exchange of ions, secondary messengers
and other small molecules in a process known as gap junctional
intercellular communication (GJIC) [1]. The protein constituents of
gap junctions, connexins, oligomerize to form connexons that trafﬁc
to the cell surface where they may function as hemichannels. Con-
nexons proceed to dock with connexons from the adjacent cell to
form gap junction channels [2,3]. A few to thousands of gap junction
channels cluster to form gap junctions that vary considerably in size
[4,5] (Fig. 1). There are 21 unique connexin genes in the human gen-
ome [6,7] and two ormore of these familymembranes are routinely
co-expressed within the same cell type [3]. Co-expressed connexin
isoforms frequently and selectively combine to form both homo-
meric and heteromeric hemichannels aswell as homotypic and het-
erotypic intercellular gap junction channels [3]. Most importantly,
these diverse combinations of connexins create different types of
channels with unique properties: channels can differ in ionic con-
ductance, permeability to various molecules and sensitivity to volt-
age or pH [5,8]. These unique properties likely reﬂect distinct
physiological roles for diverse gap junction channel types in differ-
ent tissue types.2. Germ line mutations in connexin encoding genes and disease
Connexin mutations underlie several human diseases [9–12].
For example, numerous mutations in the gene encoding Cx32
(GJB1) are associated with X-linked Charcot–Marie–Tooth (CMTX)
disease [13]. Mutations in the gene encoding Cx26 (GJB2) account
for roughly half of all cases of inherited non-syndromic deafness
[12,14] while a subclass of autosomal dominant mutations are
associated with skin diseases [15,16]. In another example, muta-
tions in both Cx46 (GJA3) and Cx50 (GJA8) are linked with congen-
ital lens cataracts [17,18]. In 2003, oculodentodigital dysplasia
(ODDD) became known as the ﬁrst human disease to be linked to
germ line Cx43 gene (GJA1) mutations [19]. Consistent with loca-
tion of the Cx43 gene, the ODDD locus was mapped to chromosome
6q22-q24 by linkage analysis [20] and location of the disease gene
was further reﬁned between D6S266 and D6S1639 markers [21].
ODDD is primarily an autosomal-dominant human disorder where
patients display symptoms of congenital craniofacial deformities,
anomalies of the teeth and eyes and limb deformities [21–23]. Dig-
ital malformations include syndactyly involving the third, fourth
and ﬁfth ﬁngers and camptodactyly of the second to fourth toe
[21–23]. Most ODDD patients also have mandibular overgrowth,
abnormal dentition, enamel hypoplasia and early tooth loss [19].
In addition to these clinical symptoms, patients may exhibit syn-
dromic disease symptoms that include a variety of neuropathies
(reviewed in [24]) skin disease, bladder incontinence, thermosensi-
tivity, lymphedema [25] and other conditions [19].
Fig. 1. Schematic model of Cx43 assembly into a gap junction. (A) The polytopic connexin is depicted spanning the lipid bilayer four times. (B) While a resident of the
endoplasmic reticulum Cx43 is expected to fold properly and avoid endoplasmic reticulum associated degradation. (C) Cx43 oligomerizes into hexamers or connexons a
process that completes in the Golgi apparatus. (D) Upon vesicular transport from the Golgi apparatus, connexons arrive at the cell surface where they may function as
hemichannels. Connexons dock with connexons from a neighboring cell to form gap junction channels that proceed to cluster into semi-crystalline gap junctions that may
consist of hundreds of channels.
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It is has long been known that Cx43 is a polytopicmembrane pro-
tein that passes through the lipid bilayer 4 times yielding the amino
and carboxy termini exposed to the cytoplasm [26–28]. The highly
conserved two extracellular loops form disulﬁde bonds that provide
structural determinants critical in connexin folding and connexon/
connexon interactions as two hexamers dock to form a complete
gap junction channel [29–31]. Upon channel clustering into crystal-
line-like arrays knownas gap junction plaques the assembly of a gap
junction is complete [32–34] (Fig. 1). When considering connexin
biology, there has been a remarkable and purposeful focus on
Cx43 for a number of valid reasons. First, it is by far themost broadly
and ubiquitously expressed member of the connexin family being
expressed in nearly all vital organs that include the brain, heart,
lungs, bone, stomach and intestine [3]. At the cellular level, Cx43
has been documented in well over 40 distinct primary cell types
making it themost diversely found connexin of the human anatomy
[3]. Second, Cx43 is probably the most extensively phosphorylated
connexin and distinct phosphorylation processes regulate events
related to connexin assembly, disassembly, turnover and channel
function [35–37]. Third, Cx43 has an extraordinarily rapid half-life
of only 2–4 h [38–40]. While this feature is shared by other connex-
ins, it is particularly intriguing in the case of Cx43 as this connexin
plays critical roles in vital organs such as the heart where onemight
predict it would be long lived. To put this into perspective, it is likely
that humans turnover and remodel all of their Cx43 gap junctions inthe heart every day [40]. Finally, Cx43 has a particularly long C-ter-
minal tailwhich encompasses the domains that bind to an extensive
interactome [41,42] that governs and regulates pH gating, channel
assembly, plaques size and likely numerous other events that we
are only beginning to be realize [43,44].
4. The Cx43 mutation composite
To date, there are 73 knownCx43mutations linked to ODDD that
result in the introduction of a mutational change in the ﬁrst two-
thirds of the Cx43 amino acid sequence [19,22,25,45–66] (Fig. 2).
It is notable that all but 9 of the 73 mutations are autosomal domi-
nant missense changes where a single amino acid is substituted for
another. Of these substitutions, the amino acid residue changes can
be: (a) a non-polar residue substituted for another -polar residue
(e.g., G2V); (b) an acidic residue replaced by another acid residue
(e.g., E110D); (c) a basic residue swapped for another basic residue
(e.g., R202H); (d) an acidic residue switched to a basic residue (e.g.,
E48K) or vice versa (e.g., K134E); or (e) the introduction of prolines
into the polypeptide to induce ‘‘kinks’’ into the sequence (e.g.,
L113P). In essence virtually all categories of conserved and non-con-
served amino acid substitutions in the Cx43 polypeptide sequence
results in ODDD nomatter where the mutation occurred in the ﬁrst
2/3rd segment of the gene sequence. Only three autosomal domi-
nant frame-shift mutants have been identiﬁed to date and both
the fs230 (2 variants with different sequence extensions) and
fs260 mutations lead to a series of non-sense amino acids before
Fig. 2. A composite map of the Cx43 polypeptide depicting the sites of ODDD-linked mutations. Note that all but 9 of the 73 mutations shown are autosomal dominant where
a single amino acid is substituted for another. Only two autosomal recessive mutations in the gene encoding Cx43 have been linked to ODDD.
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Twodeletionmutants have been reportedwhere theVESA sequence
is eliminated from the 1st extracellular loop domain and the phen-
ylalanine at 169 is lost from within or near the 3rd transmembrane
domain. Two further mutants have been reported where an amino
acid is duplicated (e.g., Q49 and F52) within the 1st extracellular
loop region. In addition, a truncation mutation at residue 101 (e.g.,
101X) located at the beginning of the cytoplasmic loop results in
the loss of over two/thirds of the connexin molecule. In addition
to the overwhelming predominance of autosomal dominant
mutations, two autosomal recessive mutations (R76H and R33X)
have been reported [22,67]. Patients that are homozygous for the
R76H mutant not only exhibit symptoms of ODDD but also
Hallermann–Streiff syndrome characterized by a small stature,
congenital cataracts, hypotrichosis, beaked nose, skeletal anomalies
and teeth defects. Remarkably, not only are subjects that are hetero-
zygous for the R76H amino acid substitution normal but if a patient
is heterozygous for a similar R76S mutant they exhibit classical
ODDD only. Curiously, the autosomal recessive R33X mutation
would result in the premature truncation of Cx43 at residue 33 lead-
ing to patients that have no Cx43 hemichannel or channel function
[67]. The fact that a Cx43 knockout is not lethal to the patient during
development is astounding but may speak to the redundancy and
compensatory mechanisms that exist in vital organs.
Onemutation in the GJA1 gene has been linked to a developmen-
tal disorder other thanODDD [68]. In this unique study involving sixindividuals from three families, an autosomal recessive missense
mutation causing a R239Q change in the amino acid sequence was
found to cause craniometaphyseal dysplasia [68]which is character-
ized by hyperostosis of craniofacial bones but a complete absence of
classicalODDDcharacteristics involving the eyes, teeth anddigits. In
another case, the E42Kmutation in Cx43was found to be associated
with sudden infant death syndromewhich is thought to be linked to
cardiac arrhythmias [69]. Finally, in a few very rare cases, reports
have shown thatGJA1mutations can be associatedwith hearing loss
and skin disorders with little or no evidence of ODDD [70–72].
To summate, the fact thatmanychanges, nomatterhowminimal,
in the amino acid sequence of Cx43 have physiological conse-
quences highlights the conservation of themolecule and the impor-
tance of all polypeptide motifs and domains. In keeping with the
intolerance of the molecular structure to changes introduced by
mutations we now know that each segment of Cx43 has unique
and sometimes overlapping functions. The N-terminal domain is
important in channel gating andoligomerization [73–76]. The trans-
membrane domains align precisely to establish a gap junction pore
that can be gated by voltage, pH, phosphorylation and calcium as
well as regulate heteromeric channel compatibility [75,77,78]. The
extracellular loops require essential and precise disulﬁde bonds to
ensure that proper channel docking is orchestrated across the gap
junction gap [75]. The cytoplasmic loop contains interactive motifs
for binding the C-tail during pH gating [79] and also a few putative
binding sites for members of the connexin interactome [41].
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suggests that the GJA1 gene is resistant to mutation or such muta-
tions may be lethal during development.
5. Mechanisms of disease linked to Cx43 mutations
Five potential major classes of connexinmutants are possible and
four of these classes are now known to occur in Cx43mutants linked
toODDD.Theﬁrst includes, onﬁrstpass, thosemutations thathaveno
discernible effect on the normal operation of the gap junction chan-
nel, and could effectively be considered benign polymorphisms. The
Cx30 T5M mutant might be considered a member of this class as it
has been reported to retain signiﬁcant channel function but yet
causes hearing loss (Berger et al. 2014, resubmitted). In another
experimental case, while the disease-linked G2V mutant exhibits a
complete loss of channel function, the G2S mutant, which has not
been found to be disease causing, has full or even enhanced channel
function [80]. It has yet to be discovered if a fully channel competent
mutant can be linked to ODDD. If such a situation does arise, the fact
that the mutant is disease causing would likely reﬂect our lack of
understanding of more subtle changes in the regulation of such a
channel or hemichannel that is formed by the mutant either alone
or in combinationwith co-expressedwild typeCx43. The secondmu-
tant class includes mutants that continue to assemble into gap junc-
tion channels, but clearly have documented reductions in channel
function. For example, several mutant forms of Cx32 associated with
CMTXhavebeenshowntohavealtered conductance,permeability, or
gating properties [81]. In Cx43, the I130Tmutant would be an exam-
ple of amutant that has documented attenuation of channel function
or altered channel regulation [82–85]. The third class of mutants in-
cludes those with altered intracellular transport and assembly as
demonstrated for some Cx32 mutants associated with CMTX [86] or
Cx26 mutations linked to deafness and skin disease [87]. The fs230
and fs260Cx43mutants are excellent examples ofwhere themutants
take up residence in the endoplasmic reticulum or Golgi apparatus,
respectively and/or fail to pass the necessary quality control mecha-
nisms that surveys mis-folded or aberrant proteins [88,89]. These
mutants may in fact be functional if successfully transported to the
cell surface in association with wild type proteins but this has yet to
be clearly established. The fourth class could represent gain-of-func-
tionmutantswherehemichannelor channel function is enhancedbe-
yond what is observed for wild-type Cx43. The G138R mutant is one
suchmutant where it has been documented to have increased hemi-
channel function [90,91], albeit a complete loss of gap junction chan-
nel function. Finally, in the ﬁfth class, Cx43 mutants may efﬁciently
transport to the cell surface and assemble into gap junction plaques
but they are functionally dead. The G21R mutant is an excellent
exampleof suchamutant [92]. Cautionneeds tobeexercised indeﬁn-
ing this class of mutants as being fully competent in their ability to
assemble into gap junctions as this is routinely deﬁned by evidence
of anti-Cx43 antibodyorGFP labeledplaque-like structures and resis-
tance of the gap junctions to detergent solubilization. Both of these
criteria could be considered consistent with complete gap junction
plaque assembly but are not deﬁnitive as conﬁrmation of the proto-
typical gap junction structure at the electronmicrocopy has not been
demonstrated. Nevertheless, this class of Cx43 mutants would be
transported to the cell surfacebut result in functionally inactivechan-
nels, possibly reﬂecting improper oligomerization during transit or
defects in hemichannel docking.
6. Structure and function lessons learned from examining Cx43
mutants
For many years investigators have been performing mutational
and chimeric analysis of Cx43 in order to elucidate the structural
and functional relationships within the Cx43 polypeptide. Whilethis has yielded many novel insights, nature has provided an
extensive mutational toolkit that can, in turn, be used to assess
the importance of individual amino acids or motifs for the proper
Cx43 folding, trafﬁcking and function. Of the 73 mutants that have
been linked to ODDD, over 20 have been engineered and expressed
in reference cell systems, organotypic cultures or mice in order to
assess how each mutation alters the structure or function of Cx43
[24,80,84,85,88,90,92–99] (Fig. 3). While this approach yields
important insights into the underlying molecular and mechanistic
causes of ODDD, other basic properties governing Cx43 channel
assembly and function can be ascertained. For example, using the
knowledge that the G2V, D3N, L7V, L11P, Y17S and S18P mutants
were all loss-of-function mutants [80] together with the published
3.5 A resolution crystal structure of Cx26 [100] one could predict
that that N-terminal of Cx43 may in fact be positioning itself in
the pore of the Cx43 channel [80]. Such a prediction was supported
by the kinked a-helical NMR structure of a 23mer polypeptide
encoding G2 or G2V. The disease-causing valine at position 2
would establish an interaction with W4, an amino acid predicted
to be important in intramolecular interactions with key
residues within the 1st transmembrane domain (I34, L35). Upon
engineering the W4A mutant it was found to generate a ‘‘kinkless’’
polypeptide and also was non-functional. Finally, NMR analysis
suggested that a G2S substitution may promote a channel open
state due to the small side chain. Not only was the G2S mutant
fully functional but it exhibited gain-of-function properties [80].
Collectively, these studies supported the notion that Cx43, like
what has been proposed for Cx26 [100], may have the N-terminal
position at or in the channel where it could interact with the 1st
transmembrane domain actively participating in the open and
close state of the channel. While this model remains to be
conﬁrmed and fully tested it is an example of where naturally
occurring disease-causing mutations can be strategically combined
with artiﬁcial mutants to assess the structural architecture of a
Cx43 motif.
7. Dominant and transdominant properties of Cx43 mutants
Since ODDD is primarily an autosomal dominant disease [45] it
is assumed that wild-type Cx43 and mutant Cx43 are always co-
expressed in any cell that is programmed to express Cx43. Such a
condition raises three possibilities as to how the mutant and
wild-type Cx43 may interact. First, the wild-type Cx43 may par-
tially rescue the function of the Cx43 mutant and maintain Cx43-
based coupling at a level above 50%. To date there is no evidence
in the characterized library of Cx43 mutants that such a situation
exists. This may not be surprising as we know that heterozygous
Cx43 knockout mice are relatively disease-free [101] and do not
exhibit any phenotypes that mimic the clinical presentation of
ODDD in humans. Thus, disease may not present in patients if
the overall based level of Cx43-GJIC is above 50%. Second, mutant
Cx43 may retain some residual channel function and together with
co-expressed wild-type Cx43 maintain Cx43-based GJIC coupling
at or greater than 50%. The I130T mutant would ﬁt in this
classiﬁcation as its overall channel function when express alone
is estimated to be 20% of that of wild-type Cx43 and overall
Cx43-based coupling in cells engineered to express both the
I130T mutant and wild-type Cx43 remains near 50% [82]. This sit-
uation is also observed in isolated cells from genetically-modiﬁed
mice where both wild-type and the I130T mutant are expected
to be co-expressed at equal ratios [82,83,94]. The third group of
Cx43 mutants is likely the biggest class where the mutant acts as
a dominant on co-expressed Cx43 resulting in total Cx43-based
coupling to be well below 50%. The G21R, G138R and the frame-
shift mutants are excellent examples of this class of mutants
[89,92,99,102]. This situation has been shown to also occur in
Fig. 3. A model depicting the ODDD-linked mutants that have been expressed and characterized in reference cells, organotypic constructs and/or in mice. Note that the vast
majority of mutants studied did not assemble into functional gap junctions (yellow). Six mutants have been reported to have residual gap junction channel function (blue)
while 3 mutants have been observed to have gain-of-hemichannel-function (purple). Note that the I130T and G138R mutations used to generate genetically-modiﬁed mice
are both located in the cytoplasmic loop region of Cx43.
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tant and mimic clinical features of ODDD [82,97,103,104].
Since most cells in the human anatomy express two or more
connexins and since Cx43 is by far the mostly ubiquitously ex-
pressed connexin, the obvious question is whether Cx43 mutants
can crosstalk and exhibit transdominant negative properties on
other co-expressed connexin family members. On ﬁrst pass, the
co-expressed connexins to consider are ones that previously have
been shown to co-oligomerize or interact with Cx43. These con-
nexins would include Cx37, Cx40 and Cx45 although this list is
probably incomplete due to the fact that only a limited number
of connexins have been tested [105–108]. Evidence for this trans-
dominant negative effect is sparse and this may explain why the
hearts of ODDD patients are relatively unaffected even though
cardiomyocytes co-express Cx40 or Cx45 together with Cx43. Here,
co-expressed connexins may act to salvage the heart from exhibit-
ing a disease phenotype in ODDD patients even in the absence of
any increase in expression. On the other hand, bone development
and remodeling anomalies are common in ODDD patients, and it
is well known that osteoblasts and osteocytes express Cx43,
Cx45 and Cx46 [91,109–111]. In this example it is likely that
mutant Cx43 is involved in dominant and/or transdominant
action on co-expressed wild-type connexins. In another case, the
autosomal recessive Cx43 R33X mutant was found to exhibittrans-dominant effect on GJIC in reference cells engineered to ex-
press the mutant together with Cx40 [112]. A more remote option
but yet still possible is that mutations in Cx43 expands their capac-
ity to interact with a greater variety of connexin family members
beyond what is possible for wild-type Cx43. While this has yet to
be documented for Cx43, disease causing Cx26 mutants have been
occasionally shown to be capable of acting as trans-dominant
negatives on the function of wild-type Cx43 [87,113]. These later
two scenarios may explain why frame-shift Cx43 mutants (e.g.,
fs230, fs260) cause skin disease where potential interactions with
up to 8 other connexins are theoretically possible if the mutants
acquire the gain-of-function capacity to interact with any of the
keratinocyte connexins.
8. Lesson learned from mouse models of ODDD
Creation of mice that harbor ODDD-linked mutation was recog-
nized in the last decade as a necessary strategy to elucidate the
pathophysiological mechanisms of the disease and to uncover sub-
clinical disease that may only be revealed upon injury or comor-
bidities. While cell reference models and organotypic cultures
have been successfully used to assess the ability of Cx43 mutants
to trafﬁc, assemble and function the fact that mutant expression
is not regulated by the endogenous Cx43 promoter nor is the dose
Fig. 4. Phenotypic differences between mouse models of ODDD. Low magniﬁcation
images of female ODDD mice harboring the G60S or I130T mutants revealed that
the Cx43G60S mice are substantial smaller with less body weight than their 3 week
old matched littermate wild type controls. Conversely, 6 month old Cx43I130T mice
and their matched littermate wild type controls are of similar size and weight.
These ﬁndings suggest that each mouse model of ODDD may in fact reveal
development differences that are unique to each ODDD causing mutation.
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studies. Since ODDD is predominantly an autosomal dominant dis-
ease it is critical to assess the consequence of any of the mutants in
native tissue where the Cx43 gene is under the control of its native
promoter and where the ratio of the mutant to wild-type Cx43 is
expected to be 1:1. The best means to solve both of these issues
is to use genetically-modiﬁed mice.
The ﬁrst generation of mice engineered to examine the relation-
ship between Cx43 mutations and disease was acquired through
an N-ethyl-N-nitrosourea screen where heterozygous mice were
identiﬁed that harbored a missense mutation in the Gja1 gene
resulting in a glycine to serine amino acid substitution at position
60 (mice referred to here as Cx43G60S mice) [103]. Although this
mutation has not been identiﬁed in patients with ODDD, the mu-
tant mice exhibit many of the same phenotypic features as ODDD
patients, including fusion of some of the toes (syndactyly), absence
of the middle phalanx of the ﬁfth digit of the hind limbs, small
eyes, craniofacial bone defects and enamel hypoplasia [103]. To-
gether with genetically matched littermate controls, Cx43G60S mice
have proven to be extremely valuable in providing insights into or-
gan development and function, tissue differentiation, sub-clinical
disease, wound healing and several other pathophysiologies
[82,93–95,103,104,114–120]. To that end, there has been numer-
ous papers published using this novel mouse model of ODDD high-
lighting the versatility and importance of mouse models of human
disease [82,93–95,103,104,114–120]. In many studies, cells were
removed from vital organs and cultured to allow for cell and
molecular assessment of GJIC and the potential dominant and/or
transdominant effect the G60S mutant exhibited on co-expressed
wild-type and other connexin family members. Intriguingly, when
cultured granulosa cells from G60S mutant mice were assessed for
GJIC, these cells that only express Cx43 were found to contain only
10–15% normal Cx43-based GJIC suggesting that the mutant was
exhibiting a strong dominant-negative on the function of co-ex-
pressed Cx43 [103]. By extrapolation and through further analysis,
it is likely that Cx43G60S mice have less than 20% Cx43 based-GJIC
in any tissue or cell that is programmed to express Cx43. However,
there may be exceptions to this observation as one study showed
that Lucifer yellow and sulforhodamine-B transfer was not reduced
in astrocytes where multiple connexins may be co-expressed to ac-
count for the loss-of-function G60S mutant [121].
To gain further insight into the role of Cx43 in development and
disease, two naturally occurring Cx43 gene mutations were used to
engineer genetically-modiﬁed mouse lines, Cx43I130T and
Cx43G138R [83,91]. In both cases, many common features of ODDD
were mirrored in these novel mouse models of human disease and
these mice further highlighted subclinical disease that may also
exist in the ODDD populous but remain less well documented. In
Cx43I130T mice, GJIC coupling and the most phosphorylated forms
of Cx43 were reduced and there was a slowing of the conduction
velocity in the heart with an increase in sensitivity to ventricular
tachyarrhythmias [83]. Further investigation revealed that these
mice and the Cx43G60S mice had myogenic, and likely neurogenic,
bladder defects but this only manifested in a bladder function
change in the Cx43I130T mice [94]. Variations in the phenotype of
genetically-modiﬁed mice that harbor different missense muta-
tions in the Cx43 gene was also seen in the fact that the Cx43G60S
mice are consistently smaller than age-matched littermate con-
trols while the Cx43I130T mice are of similar size and weight
(Fig. 4). In still another example, in the mammary gland where
Cx43G60S mice had a clear and distinct defect in milk ejection dur-
ing lactation, this defect was completely absent in Cx43I130T mice
[122,123]. These differences highlight the need to include multiple
mouse models of ODDD to fully understand the pleiotropic varia-
tions in phenotypes that exist in these mice that may also provide
a deeper understanding as to why some ODDD patients have agreater disease burden than others. To that end, Cx43G138R mice
were engineered to conditionally express the Cx43 mutant and
found to also mimic the commonly found developmental charac-
teristics of ODDD [91]. Furthermore, mice conditionally engineered
to expressing the G138R mutant in the heart were found to be sus-
ceptible to spontaneous arrhythmias probably as a result of a
reduction in properly phosphorylated Cx43, reduced GJIC and an
increase in ATP-release in cardiomyocytes [91]. Later Cx43G138R
mice were used to show that Cx43-based GJIC is required for prop-
er morphogen expression in limb development [96]. Here the
authors showed that mice harboring the G138R mutant with syn-
dactylies had reduced levels of sonic hedgehog and bone morpho-
genic protein 2, that together with increase ﬁbroblast growth
factors lead to defective interdigital apoptosis [96]. These ﬁndings
provided a rationale as to why ODDD patients nearly always exhib-
ited syndactylies.
9. Human research models of ODDD
In more recent years the challenge has been to examine Cx43
function in the most relevant models. To that end, obtaining hu-
man research models of human disease remains a challenge when
considering rare connexin-linked diseases. Genotyping children
with hearing loss for Cx26 and/or Cx30 gene mutations has now
become a standard level of care in many developed nations owing
to the fact that 40–50% of children with congenital neurosensory
deafness harbor these mutations. However, the consequence of a
positive-test has little clinical implication as no speciﬁc treatments
for patients harboring connexin gene mutations is currently em-
ployed or available. At the research level, several laboratories have
obtained skin biopsies to examine the expression and localization
of connexins from patients that exhibit skin diseases where
Cx26, Cx30.3, Cx30, or Cx31 gene mutations are involved
[16,124–127]. Typically, ethical approval for such biopsies are
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and patient discomfort. However, three signiﬁcant obstacles exist
in attempts to obtain and examine tissues or cells from ODDD pa-
tients. First, ODDD is rare with only a few thousand cases clinically
reported and with a population projection that less than 1 per
100,000 will present with ODDD. Thus, patient samples will always
be difﬁcult to obtain [45]. Second, given the rarity of the disease, it
is unlikely that one would be able to identify more than a single
family with a given mutation, making generic statements that
transcends ethnic backgrounds, sex and age, difﬁcult at best. Final-
ly, once a patient is identiﬁed, resecting tissues where disease
manifests is nearly impossible given that the common clinical
development disorders of the hands, feet, eyes, bone and teeth
are not readily accessible.
In one study, we were fortunate to have obtained skin dermal
ﬁbroblasts from two ODDD patients harboring the D3N and
V216L mutations as well as unaffected close relatives which al-
lowed for direct biochemical and molecular comparisons of cells
that are on a similar genetic platform [95]. While neither of these
patients exhibited any overt evidence of skin disease, previous
wound healing studies in Cx43G60S mice suggested that there
may be an underlying wound healing delay and this condition
was deemed to be due in part to phenotypic changes in the dermal
ﬁbroblasts. In the human dermal ﬁbroblasts, the V216L mutant
exhibited strong dominant-negative properties on co-expressed
Cx43 while only a modest effect was exhibited by the D3N mutant
[95]. Both mutant expressing dermal ﬁbroblasts grew slower and
migrated less well than their family matched unaffected control
cells, suggesting that these cells may not perform as well in wound
healing. This hypothesis was supported by the restricted ability of
mutant expressing cells to respond to TGFb and increase the
expressing of smooth muscle actin as this would be expected of
cells undergoing differentiation into myoﬁbroblasts during the
wound healing response [95]. Collectively, these studies suggest
that at least some ODDD patients would have compromised wound
healing. Looking to the future it would be important to obtain der-
mal ﬁbroblasts and other cell types from patients harboring a wide
array of ODDD-linked mutations to explore other subclinical dis-
eases that may exist in ODDD patients.
10. Summary and future perspectives
Examination of disease-causing Cx43 mutants using cell
expression systems, organotypic cultures, genetically-modiﬁed
mice and patient cells has led to a number of core discoveries that
improves our understanding of how Cx43 functions and in what
way any number of changes in Cx43 function can lead to disease.
It is clear that one cannot simply assess whether a mutation is con-
served or non-conserved nor assess the site of the mutation and
predict patient disease load. Conversely, we can predict with some
certainty that many changes in the Cx43 amino acid sequence will
have disease consequences suggesting that Cx43 has a low toler-
ance for change if its full range of cellular function is to be main-
tained. We have also seen that in many cases, but not all, the
mutation will cause a loss-of-channel function while a few muta-
tions appear to provide a gain-of-function advantage (e.g., in-
creased hemichannel function) that can be equally damaging to
human development and physiology. While many mutants act as
dominant-negatives, a few do not, raising questions as to why pa-
tients still present with the common clinical symptoms. Con-
versely, only a few mutants so far have been shown to have any
transdominant-negative effects which may be surprising given
the wealth of cells that co-express connexin family members that
are capable of interacting with Cx43. Lastly, it appears likely that at
least some patients have subclinical disease (e.g., delay in woundhealing) that may only present upon injury or organ distress
caused by other co-morbidities that are acquired during the aging
process. Circumstantially, it is intriguing that more disease in
ODDD patients becomes evident during aging which may be seren-
dipitous or linked to organs that suffer from compromised Cx43
function for decades.
Looking forward there are many outstanding questions that re-
main. First, there is little explanation for organs like the heart not
being more dramatically affected in ODDD patients particularly
when Cx43 mutants are expressed that have a strong dominant-
negative effect on co-expressed Cx43. If co-expression of other
connexin members is sufﬁcient to rescue the organ from disease
one might predict that the bone and skin should also be protected
from disease as multiple connexin family members are co-ex-
pressed in these organs, yet this is not the case. Second, it is
remarkable that ODDD patients that may have as little as 15–20%
normal Cx43-based GJIC do not have more developmental abnor-
malities or exhibit more disease susceptibility. Thus, it would seem
much of the human physiology can tolerate and even thrive with
minimal Cx43 function. This may be due to the notion that Cx43
is produced in excess or connexin family members act in a com-
pensatory fashion even in the absence of increase expression.
Third, the question remains as to whether ODDD can be treated.
One option would be to use a pharmacology approach to increase
the functional state of Cx43. Here one would need to argue that in-
creased expression of Cx43 (both mutant and wild type) would
drive cells into a state of having enhanced overall Cx43-based GJIC.
Evidence for such a treatment option is essentially non-existent
and the pharmacology is lacking. Only an antiarrhythmic pep-
tide-based drug called rotigaptide and newer derivatives of this
peptide (danegaptide) have reached clinical trials as an enhancer
of Cx43 in cardiac pathologies [128–130]. Another theoretical op-
tion would be to design cell permeable drugs that could stimulate
the expression of a complementary member of the connexin family
(e.g., Cx40) that could serve many of the same roles of Cx43. Both
of these strategies need to be coupled to tissue delivery systems
that target the defective tissue and even then would only be appro-
priate for diseased organs that have not be subjected to permanent
and irreversible developmental anomalies (e.g., incontinence, skin
regeneration). Possibly a more realistic strategy would be to used
targeted RNAi strategies to speciﬁcally knock down the mRNA that
encodes mutant Cx43 but not wild type Cx43. Evidence exists that
a 50% complement of normal Cx43 that is unimpeded by the co-
expression of mutant Cx43 may sustain normal phenotype at least
this appears to be the case in mice that are heterozygous for Cx43
ablation [101].
In summary, it has become apparent in both mice and human-
kind that survival and health depends on the expression and func-
tion of the most ubiquitously found member of the connexin
family, Cx43. Studies into the pathophysiology of ODDD patients
and mouse models of this disease will continue to shed insights
into the mechanisms that surround the role of Cx43 in develop-
ment and also during aging where health inevitability becomes
compromised by comorbidities.
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